RealTalk MS

Episode 480: MSToronto 2026 with Dr. Jeffrey Cohen and Dr. Robert Fox

2 ноя 2026 · 36:34
Медицина

Описание

Our coverage of MSToronto 2026 continues this week with two important conversations. First, we'll hear from Dr. Jeffrey Cohen about the latest clinical findings on CAR-T cell therapy as a potential treatment for MS. Then, Dr. Robert Fox will update us on the global research portfolio being driven by the International Progressive MS Alliance.

And we have to talk about Christina Applegate. By now, the news of her misdiagnosis isn't really news. But we have some suggestions for how you might want to process that news.

We have a lot to talk about. Are you ready for RealTalk MS??!

This Week: MSToronto 2026 :22

But, first, we have to talk about Christina Applegate :46

Dr. Jeffrey Cohen discusses what the experts are learning about CAR-T cell therapy 6:51

Dr. Robert Fox shares an update on the global work being driven by the International Progressive MS Alliance 19:03

Share this episode 34:21

Have you downloaded the RealTalk MS app? 34:40

Next week 35:25

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/480

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected]
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com

DOWNLOAD: The RealTalk MS App
iOS: https://apps.apple.com/us/app/realtalk-ms/id6769516594
Android: https://play.google.com/store/apps/details?id=com.realtalkms.app&pcampaignid=web_share

PARTICIPATE: Phase 3 Clinical Trial for Orelabrutinib and Non-Active Secondary Progressive MS

Комментарии

Комментариев пока нет — напишите первый.